Abstract:
The primary liver cancer also referred as Hepatocellular carcinoma (HCC), is a lethal disease
accounts for approximately 90% of liver cancer worldwide. The major problem with HCC
is early diagnosis. PKC gamma a member of conventional PKC involved in many cancers
type but in context of single nucleotide polymorphism the protein was not much explored.
The in-silico investigation of PKC gamma SNPs via edictSNP, 2021, CADD, DANN
identify missense pathogenic mutation (K359R) rs1331234028. The AA variant of this
genotype shows strong association with HCC. The odd ratio (OR) and relative risk (RR) for
this variant was 5.194 and 2.287 respectively, having 0.0001 P-value. In-silico structural and
functional analysis predict that upon this mutation the protein stability may decrease. For
therapeutic purpose Maytansine was docked with PKC gamma which shows promising
results and can be used as inhibitor of PKC gamma. The genetic variation in PKC gamma
can be helpful in the early diagnosis of the hepatocellular carcinoma.
